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Abstract
Background: Implementation of an effective Tuberculosis Routine Surveillance System in low-income countries like
Tanzania is problematic, despite being an essential tool for the detection and effective monitoring of drug resistant
tuberculosis. Long delays in specimen transportation from the facilities to reference laboratory and results
dissemination back to the health facilities, result in poor patient management, particularly where multidrug-resistant
tuberculosis disease is present.
Methods: Following a detailed qualitative study, a pilot intervention of a revised Tuberculosis Routine Surveillance
System was implemented in Mwanza region, Tanzania. This included the use of rapid molecular methods for the
detection of both tuberculosis and drug resistance using Xpert MTB/RIF in some Mwanza sites, the use of Xpert
MTB/RIF and Line Probe Assay at the Central Tuberculosis Reference Laboratory, a revised communication strategy
and interventions to address the issue of poor form completion. A before and after comparison of the intervention
on the number of drug resistant tuberculosis cases identified and the time taken for results feedback to the
requesting site was reported.
Results: The revised system for previously treated cases tested at the Central Reference Laboratory was able to
obtain the following findings; the number of cases tested increased from 75 in 2016 to 185 in 2017. The times for
specimen transportation from health facilities to the reference laboratory were reduced by 22% (from 9 to 7 days).
The median time for the district to receive results was reduced by 36% (from 11 to 7 days). Overall the number of
drug resistant tuberculosis cases starting treatment increased by 67% (from 12 to 20).
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Conclusion: Detection of drug resistance could significantly be enhanced, and delays reduced by introduction of
new technologies and improved routine surveillance system, including better communication using mobile
applications such as ‘WhatsApp’ and close follow-ups. A larger scale study is now merited to ascertain if these
benefits are robust across different contexts.
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Background
Tuberculosis (TB) is the highest single cause of death
worldwide from an infectious disease and continues to
be a major public health problem [1]. The World Health
Organization (WHO) estimates, 10.4 million people
contracted TB in 2016 of which 4 million of these cases
were undiagnosed. 480,000 were estimated to be cases
with TB that is resistant to at least Isoniazid (INH) and
Rifampicin (RIF), with or without resistance to other
first-line drugs (MDR-TB) cases of which 6.2% were Ex-
tensively Drug-Resistant TB (XDR-TB). 1.3 million
people were estimated to have died of the disease [1]. In
a resource-constrained setting, diagnosis of MDR-TB
can take many weeks caused by long delays in starting
and completing diagnosis with limited diagnostic facil-
ities that can detect drug-resistance [2]. Delay in diagno-
sis and treatment has serious consequences for disease
control at both the individual and the community levels
[3]. The strength of the TB laboratory network is often a
direct reflection of the success of the TB Control Pro-
grammes [4]. Poor TB case detection and rising TB drug
resistant are in part the result of historically neglected
laboratory services, slow technology transfer, and a lack
of new more accurate TB diagnostic tools [5]. The
WHO recommends rapid and sensitive diagnostic
methods that provide information on drug resistance
(i.e. methods such as GeneXpert (Xpert MTB/RIF) and
Line-Probe Assays (LPA) [6]). The LPA Genotypic (mo-
lecular) tests for identification of isoniazid and rifampi-
cin resistance to first-line anti-TB drugs [7], and
Genotype® MTBDRplus assay have shown promise for
the diagnosis of drug resistant TB for the second line
(SL-LPA) anti TB drugs. These tests can be performed
in a single working day and detect the presence of muta-
tions associated with drug resistant TB [8, 9]. Xpert can
be used as a point of care technology in some contexts
and can reduce the time between specimen collection
and diagnostic result [10].
A successful continuous Routine Surveillance System
(RSS) is an important element in the process of detect-
ing and monitoring drug resistant TB. The existing RSS
of the National TB and Leprosy Program (NTLP) in
Tanzania shown in Fig. 1, specifies sputum specimens
should be submitted to the Central TB Reference
Laboratory (CTRL) for culture and drug susceptibility
testing (DST) for 25% of all new TB cases and 100% of
previously treated TB cases [11]. However, these per-
centages for DST at the CTRL have historical not been
achieved. Indeed for previously treated TB only 61% of
cases were sent for testing even in the best year of the
three-year period investigated, suggesting cases of drug
resistance are likely to have been missed [12]. This study
focused on the previously treated TB cases because that
is where most MDR TB cases are found [13, 14]. Failure
to appropriately track these cases could lead to the
emergence of XDR-TB. Qualitative findings showed that
the system of TB specimen transportation in Tanzania
was a major problem in remote health facilities as there
were no reliable and frequent means of transport [12].
The existing RSS was underperforming in relation to the
feedback and communication of the drug susceptibility
testing results from the CTRL to the peripheral health
facilities [12]. Based on these findings, in this study a re-
vised routine surveillance system was designed and
piloted in Mwanza region, Tanzania. The design took
account of the weaknesses identified from the earlier
qualitative study [12] and changes in the availability of
molecular diagnostic techniques. A ‘before and after’
comparison was conducted of the performance of the
RSS. Measurements were taken to assess the effect of
the revised RSS on the number of specimens received
and tested for drug susceptibility, the time for specimen
transportation and results feedback, and the number of
MDR-TB cases detected.
Consequently, a study designed to understand the po-
tential effects of a revised routine surveillance system for
previously treated TB cases on delays and level of MDR-
TB diagnosis by piloting the revised approach in
Mwanza region, Tanzania.
Methods
Study site
The study was carried out in four districts of Mwanza
region (population of 2.77 million with high burden of
HIV/AIDS [14]) in Tanzania from 1st March 2017 to 1st
March 2018. Mwanza was chosen because it is a remote
area with a high TB case load and therefore an area
where transportation of specimens is particularly
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challenging. At the time of conducting this study, there
were eighty smear microscopy diagnostic centres, with
five centres installed with Xpert for routine diagnosis.
The region is 1142 km by road from Dar es Salaam
where the CTRL is located where Drug Susceptibility
testing currently takes place. Due to its size and location
piloting the revised RSS in Mwanza was considered an
effective means of evaluating impact of the revised RSS.
Study design and population
A prospective pilot study of the revised RSS for previ-
ously treated TB cases was conducted with ‘before and
after’ quantitative analyses of impact.
Study procedure
Revised routine surveillance system
The current (‘Before’) RSS is described in Fig. 1. In the re-
vised RSS (‘After’), sputum specimens were collected from
four study sites (shown in Fig. 2) and were examined using
the molecular method in a modified algorithm for detec-
tion of drug resistant TB. The algorithm design was in
two parts. Part “A” for sites without Xpert capacity where
smear microscopy was used as the primary tool for TB
diagnosis, or a site where neither microscopy nor Xpert
MTB/RIF were available known as non-diagnostic centres.
If tests undertaken in the peripheral laboratory were
smear positive or could not be tested, then a sputum spe-
cimen was transported to the nearest Xpert site. Part “B”
for sites where an Xpert had been installed and was used
as the primary diagnostic tool, where only specimens that
were detected as Rifampicin resistant were sent to the
CTRL for confirmatory LPA testing (Fig. 2).
Specimen collection, transportation and processing
At Peripheral sites in Mwanza, specimens collected from
previously treated cases in non-diagnostic sites were trans-
ported to microscopy sites for diagnosis. Specimens col-
lected at sites with microscopy together with those
received from non-diagnostic sites were examined by
Light Emitting Diode (LED) microscopy. Microscopy re-
sults were communicated to the clinician for patient man-
agement. Positive smear specimens were then transported
to the nearest Xpert site using motorbikes commonly
known as “bodaboda”. Specimens were not batched before
transportation as with the existing RSS, as it had been
noted this could lead to many days delays. The bodaboda
was chosen as it was seen as a reliable transportation sys-
tem in the peripheries and was identified and registered in
collaboration with Koninklijke Nederlandse Centrale Ver-
eniging tot bestrijding der Tuberculose (KNCV).
At the five Xpert sites in Mwanza, specimens were ana-
lysed using Xpert. When rifampicin resistance was detected
Fig. 1 Specimen flow for the existing Routine Surveillance System
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the specimen was sent to the CTRL by the Expedited Mail
Services (EMS), without batching, to be tested for both first
and second-line anti TB drugs using LPA. This was commu-
nicated to the CTRL through WhatsApp groups for easy
tracking and sharing information in case of any problems
(Fig. 2). The WhatsApp groups were initiated for easy com-
munication due to the lack of official telephone lines and
internet connectivity at the Mwanza study sites and the
CTRL. The WhatsApp was instantaneous, affordable and
reachable to all at any time. Various groups were created by
the NTLP Manager such as Vitendanishi for supplies; to fol-
low up laboratory supplies availability, stock status and any
other issues regarding the TB laboratory services across the
country. The MSD group for Medical Store Department; for
tracking any orders requested through NTLP. The What-
sApp groups facilitated the resolution of any concerns in a
timely manner and eased results dissemination, consequently
shortening both transit and overall turnaround time.
On arrival at the CTRL, the specimens with their ac-
companying revised forms were checked for complete-
ness and accuracy against the specimen container.
Missing information was communicated to the requester
immediately to rectify the identified problems. All speci-
men examination procedures were carried out in a Bio-
safety cabinet class II. Results were recorded in the TB
laboratory registers and on the TB laboratory request
forms. The forms were immediately sent back to the re-
questers through EMS.
Summary of interventions included in the revised RSS
In summary, the key difference in revised RSS are: changes
in diagnostic approach by using Xpert at the local site in
Mwanza and Xpert and LPA at the CTRL; introduction of
reliable specimen’s transportation from the remote sites in
Mwanza using Bodaboda; changes in results dissemination
to the requester including copies to the Regional TB and
Leprosy Coordinator (RTLC); close monitoring of speci-
men transportation time by the CTRL with expectation of
a minimum of 4 days and maximum of 7 days; comparison
of the number of specimens received at the CTRL versus
cases notified and communicated to the RTLC; TB labora-
tory request forms were revised to make them clearer and
the TB laboratory register modified to accommodate the
changes; supportive supervision and mentoring schedule
was created and shared with the Mwanza team; improved
communication between the CTRL and the health fa-
cilities in Mwanza region through WhatsApp groups
“Mwanza family”, RTLC, DTLCs and CTRL staff; all
specimen transportation used a system where a speci-
men is inserted in a clear zip bag and put in a small
plastic container with a screw cap (primary container)
together with absorbent material in case of leakages.
This is placed in a plastic container (secondary con-
tainer) together with the completed TB laboratory re-
quest forms and then put in either a metal, plastic or
cardboard box [15, 16] know as a Triple pack and
specimens were transported to the intended study site
Fig. 2 Specimen flow for the revised Routine Surveillance System
Doulla et al. BMC Infectious Diseases          (2020) 20:594 Page 4 of 11
on the day of collection whenever possible even if it was
just a single specimen. To support all this training on the
revised RSS was conducted at all study sites in Mwanza
and the CTRL.
The primary outcomes of the study were the impact
of the revised RSS on specimen transit time and turn-
around time. Routine NTLP data from 2015 were
used to determine the sample size. The study sample
size was powered based on the turnaround outcome.
A total of 315 specimens were required to show a
significant reduction in this time using a 95% confi-
dence interval, 80% power, and hypothesised average
difference of 10 days with a population standard devi-
ation of 44.88.1
Population standard deviation of 44.81
Estimated Turnaround time for Mwanza Region for the year 2015
TAT calculation = time from specimen receipt at CTRL to the time results
were reported and communicated back to the requester
Year N (TAT) mean (TAT) sd (TAT) min (TAT) max (TAT)
2015 69 88.87 44.88 12 304
Key: N- Number; TAT- turnaround time; CTRL-
Central Tuberculosis Reference Laboratory; sd- standard
deviation.
Formula
n ¼ Zα=2þ Zβð Þ22σ2=d2
Where;
Zα/2 is the critical value of the Normal distribution at
α/2 = 1.96.
Zβ is the critical value of the Normal distribution at
β = 0.84.
σ2 is the population variance.
d is the difference you would like to detect.
Sample size titration.
Z5%/2 = 1.96 Z20% = 0.84 sd d n
1.96 0.84 44.8 5 1259
1.96 0.84 44.8 10 315
1.96 0.84 44.8 15 140
1.96 0.84 44.8 20 79
Data collection and analysis
Data were double entered independently into computer
database using Epidata software version 3.1, by two data
entrants, internal data consistency checks were built into
the database. Validation and consistency checks were
done by the statistician using SPSS version 17. Queries
were provided to the Data entrants for verification and
rectification and errors were corrected before analysis.
Analysis was performed on data collected from March
2017 to March 2018 in Mwanza and the CTRL. Transit
time defined as time from specimen collection to the
time the specimen is received at the CTRL and
turnaround time defined as the time from specimen
receipt to the time results were reported and
communicated back to the requester were reported.
Ethical statement
The study was approved by the Medical Research
Coordinating Committee of the National Institute for
Medical Research in Tanzania, (NIMR); reference no.
NIMR/HQ/R.8a/Vol. IX/2347 and the Liverpool School
of Tropical Medicine (LSTM). No oral or written
consents were obtained.
Results
Results before pilot interventions implemented 2016/
2017
There were 75 Mwanza specimens analysed at the CTRL
from March 2016 to March 2017, of these 48 (64%)
were analysed, 27 (36%) had missing information and
could not be analysed. No positive isolate specimens
were received from the Zonal culture laboratory in
Mwanza (Table 2). The transit time recorded for both
sputum and isolates showed 44% of specimens were
received after 21 days. The Interquartile Ranges cut off
points were 25th First Quartile and 75th third Quartile.
Overall the median and (interquartile range - IQR) was
12 (51) days in 2016/2017 (Table 2). The turnaround
time had an overall median (IQR) of 62 (10) days
(Table 4).
A total of 471 specimens were collected during the
study period from March 2017 to March 2018 (2017/
2018). 273 (58.0%) specimens were received in the
Mwanza sites and 198 (42.0%) at the CTRL. Of those
received at the CTRL, 185 (93.4%) were sent for
examination with LPA. Of these 1 had no
Mycobacterium TB detected and 5% of the
uncontaminated specimens were found to be resistant to
Rifampicin or Isoniazid or both (Fig. 3, Table 1).
Figure 4 shows the variation in the number of
specimens received at the CTRL throughout the study.
This shows the largest number of specimens were
recorded in May 2017, January 2018 and March 2018.
Few specimens were received in April and December
2018 (Fig. 4).
In March 2017/2018 the total number of specimens
that were examined at the CTRL was 185, of those 63
(34%) were sputum specimens from the periphery and
1https://select-statistics.co.uk/calculators/sample-size-calculator-two-
means/ 15th May 2016
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Table 1 Drug susceptibility testing – Line Probe Assay at the CTRL
S/N LPA – CTRL Positive isolate - Zonal TB culture laboratory Sputum specimens – peripheral laboratory Total
1 RIF (R), INH (R) 5 (3%) 0 (0%) 5 (3%)
2 RIF (R) 1 (1%) 3 (2%) 4 (2%)
3 INH (R) 0 (0%) 0 (0%) 0 (0%)
4 Sensitive to both RIF and INH 115 (64%) 56 (31%) 171 (95%)
5 Total 121 (68%) 59 (33%) 180 (100%)
6 Contaminated 1 (1%) 3 (1%) 4 (2%)
Key: LPA Line Probe Assay, TB Tuberculosis, CTRL Central Tuberculosis Reference Laboratory, RIF (R) Rifampicin resistant, INH (R) Isoniazid resistant
Fig. 3 Specimens Analysed 2017/2018 – a pilot study
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122 (66%) were Mycobacterium TB positive isolates
from Zonal TB culture laboratory.
Transit time (time from specimen collection to the time
the specimen is received at the CTRL)
Transit time for both sputum and isolates ranged from 2
to 21 days and 21% of specimens were received after 21
days. The median and (interquartile range - IQR) transit
time was 10 (9) days (Table 2). This compares to the
median and (interquartile range - IQR) of 12 (51) days
in 2016/2017.
Out of 273 specimens referred to the Xpert sites in
Mwanza region; 62 (23%) were rejected. 128 of the 151
(85%) sputum specimens were received in less than 3
days. In 2016/2017 no data was recorded for specimens
referred to Xpert sites (Table 3).
Turnaround time
Turnaround time was calculated by subtracting the
date results were reported from the date specimen
was received at the CTRL. The overall median (IQR)
turnaround time was 7 (8) days for 2017/2018 and
for the 2016–2017, the median IQR was 62 (10) days.
There was a significant (p-value < 0.001) decrease in
turnaround time of 55 days after the intervention
(Table 4).
Turnaround time peripheral sites in Mwanza region
Out of 211 specimens processed, 59(28%) had missing
turnaround times. Of the 152 to known turnaround
times, 145 (95%) results were sent back in less than 3
days while 4 (3%) were sent back in more than 21 days
(Table 5).
Completeness of the filled in TB laboratory request
forms received at the CTRL from Mwanza before and
after the intervention was compared. In 2016/17 32%
had missing address information and 52% had missing
district number. In comparison in 2017/18 missing
address information dropped to 13% and missing district
number fell to 3% (Fig. 5).
The total annual previously treated cases notified in
Tanzania in 2016 were 3072 and in 2017 were 3528. The
previously treated cases notified at the National level for
Mwanza 2016 was 128 (4%) versus 2017 was 171 (5%),
the number of drug resistant TB cases starting treatment
increased by 67% (from 12 to 20) (Fig. 6).
Fig. 4 Summary number of previously treated patients’ specimens received at the CTRL
Table 2 Transit time: Number (%) of the specimen received at CTRL from Mwanza site
Year Specimen < 3 days > = 3 days & < 7 days > = 7 days & < 21 days > = 21 days Total 1st IQR 3rd IQR Median IQR
2017/2018
After Interventions Sputum 3 (5%) 18 (29%) 39 (62%) 3 (5%) 63 6 9 7 3
Isolate 0 (0%) 30 (25%) 56 (46%) 36 (30%) 122 7 34 10 27
Total 3 (2%) 48 (26%) 95 (52%) 39 (21%) 185 6 15 10 9
2016/2017
Before Intervention Sputum 13 (27%) 4 (8%) 10 (21%) 21 (44%) 48 3 54 12 51
Isolate 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0
Key: IQR Interquartile range = Third Quartile – First Quartile.
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Discussion
The study involved the design and piloting of a revised
RSS in Mwanza region. The revised RSS aimed to
address many of the issues raised in the earlier
qualitative study [12], as well as taking into account the
wider availability of molecular testing. The primary
outcomes of the study were the impact of the revised
RSS on specimen transit time and the time for drug
susceptibility results to be sent back to the requester
(turnaround time). The pilot of the revised RSS showed
significant improvements compared to the current RSS.
In particular, reduced transit times and turnaround
times for testing which would be expected to lead to
drug resistant TB patients starting treatment earlier as
well as an increase in the number identified (in this
study by around 67%). We observed the volume of
previously treated specimens received at the CTRL more
than doubled (185 in 2017/18 compared to 75 in 2016/
17). The use of local Xpert sites reduced times for
specimen transportation in Mwanza region for both
sputum and isolates to less than 3 days in most cases.
The transit time recorded for both sputum and isolate
specimens in 2017/2018 showed a median of 10 days
(IQR 6, 15) with 21% over 21 days. In comparison for
sputum specimens in 2016/2017, the median was 12
days (IQR 3, 54) with 44% taking more than 21 days.
Unfortunately, due to poor data recording in 2016/2017,
the turnaround time is only based on 8 samples where
the median turnaround time was 62 days when solid
culture was used. By comparison, the use of molecular
techniques in 2017/18 saw the turnaround time median
drop to 7 days.
In addition, the revised RSS led to 93% of the
specimens received at the CTRL being examined in
comparison to just 64% in 2016/17 before the revised
RSS was implemented. This was supported by a
reduction in missing information on laboratory request
forms.
Social media played an important role in this study.
Various groups created by the NTLP Manager such as
Vitendanishi for lab supplies, and the Mwanza family
created by the RTLC in Mwanza to enhance timely
communication with laboratory personnel, and the
DTLC in Mwanza. These groups allowed the ground
staff responsible for sending out specimens to resolve
concerns timely and eased results dissemination
consequently shortening both transit and turnaround
times. The platform was replicated in other regions
among DTLCs, RTLCs and laboratory teams. Use of
WhatsApp groups may also be a useful approach to
address other communication issues in the TB
programme and beyond.
The study had some limitations due to poor record
keeping in the historical data which made some
comparisons of performance difficult. However, to a
certain degree, this poor record keeping was also
symptomatic of the poor performing RSS. The revised
RSS record keeping has improved and this is an
additional benefit assuming it can be sustained. The
evidence from this study shows why this is important as
it can have a direct effect on patients getting appropriate
treatment and in a timely manner. There was great
variability by month in the number of specimens
transported for testing (Fig. 4) this was mainly due to
operational reasons, for example towards the end of
May 2017, there was a nationwide employees’ education
Table 3 Transit time from Mwanza study Non Xpert to Xpert sites in 2017/2018
Year Specimen < 3 days (%) > = 3 & < 7 days (%) > = 7 & 21 days (%) > = 21 days (%) Rejected specimens (%) Total
2017–2018 Sputum 128 (85) 5 (3) 1 (1) 1 (1) 16 (10) 151
Isolate 75 (62) 1 (1) 0 0 46 (37) 122
Total 203 (74) 6 (2) 1 (0.5) 1 (0.5) 62 (23) 273
Key: Rejected specimens- leakage or empty container received
Table 4 Turnaround times: Number (%) of specimens’ results
dissemination from CTRL to Mwanza sites
Specimen < 3
days
> = 3 & <
7 day
> = 7 & <
21 day
> = 21
days
Total Median IQR
2017/2018
Sputum 11 (18%) 38 (63%) 8 (13%) 3 (5%) 60 3 2
Isolate 14 (12%) 21 (17%) 54 (45%) 31 (25%) 122 7 22
Total 25 (14%) 59 (33%) 62 (34%) 34 (19%) 182 7 8
2016/2017
Sputum 0 0 0 8 (11) 8 62 10
Isolate 0 0 0 0 0 0 0
Total 0 0 0 8 (11) 0 62 10
Note: 2017/2018–3 specimens were not processed and 2016/2017–67
specimens had missing date hence excluded from the analysis
Key: CTRL Central tuberculosis reference laboratory, IQR
Interquartile range.
Table 5 Turnaround times: Number (%) of specimen results
dissemination from Xpert site to Non-Xpert sites in Mwanza
Region 2017/2018
Centre < 3
days
> = 3 &
< 7 day
> = 7 &
< 21 day
> = 21
days
Total
Diagnostic 75 (96) 2 (3) 0 (0) 1 (1) 78
Non-Diagnostic 70 (95) 1 (1) 0 (0) 3 (4) 74
Total 145 (95) 3 (2) 0 (0) 4 (3) 152
Note: 62 Specimens were excluded from the analysis
Key: Diagnostic- sites with microscopy; Non-diagnostic- site
without microscopy.
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certificates inspection for irregularities which led to the
termination of several laboratory staff and clinicians.
This exercise had a negative impact on the study. In
addition, in December 2017 and February 2018, fewer
specimens were received which might have been due to
staff shortages and some being on holidays leading to
some specimen batching.
It is clear from this study there is more to do. For
instance, even with the focus of the revised RSS, 13% of
laboratory request forms had missing laboratory
reference numbers and 3% missing addresses, although
much lower than in 2016/17. Similarly, there were
significant numbers of specimens in 2017/18 that were
not processed for a variety of reasons (i.e. in total 75 out
of 472, 15.9%) – see Fig. 3, however, again this is much
lower than in 2016/17. Moreover, in the National
Strategic Plan (NSP) it was estimated that the MDR TB
burdens were 699 and 725 for 2016 and 2017
respectively. The targets set for the region were 349 and
435, but the actual drug resistant TB cases notified were
197 and 200, which implies there remains a large
detection gap [17–19].
The study focussed on previously treated cases only,
all the interventions looked at could have equal value to
new cases, though the level of drug resistance would be
expected to be much lower.
Fig. 5 Incomplete TB Laboratory Request Forms 2016/2017 and 2017/2018
Fig. 6 Previously treated drug resistant cases detected (2016/2017 and 2017/2018)
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Conclusion
In conclusion, the revised RSS led to an increased
number of specimens received and tested at the CTRL.
The use of social media within the NTLP network led to
close follow-ups and timely response to concerns during
the piloting. The revised system was shown to reduce
delays in diagnosis and increase in drug resistant case
detection. The shorter transit times and turnaround
times are important in the diagnosis of MDR-TB and
TB control. These positive results suggest a larger scale
study involving more regions should be considered to
determine whether these benefits are robust and sustain-
able across similar settings.
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